This study confirms the central oncogenic role of BCR–ABL in the pathogenesis of chronic myeloid leukaemia, and highlights the role of targeting this tyrosine kinase as a useful tool in the clinical management of the disease. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.